Home › Peptides › CJC-1295 No DAC
CJC-1295 No DAC dosage and protocol
Last reviewed Oct 7, 2026. Editorial policy
CJC-1295 without DAC (Drug Affinity Complex) is a growth hormone releasing hormone (GHRH) analog. It stimulates growth hormone secretion and is often studied in combination with GHRP peptides.
- Vial size: 5 mg
- Reconstitution: 3 mL bacteriostatic water
- Concentration: 1.67 mg/mL
- Administration: subcutaneous
Research areas
- Growth Hormone
- Recovery
- Anti-Aging Research
- Muscle Research
Quick start
- Reconstitute: Add 3.0mL bacteriostatic water → ~1.67mg/mL concentration
- Typical daily range: 100–300mcg once daily (gradual titration)
- Easy measuring: At 1.67mg/mL, 1 unit = 0.01mL ≈ 16.7mcg on a U-100 syringe
- Storage: Lyophilized at 2–8°C; after reconstitution, refrigerate and use within 1–2 weeks; for longer storage, freeze at ≤−20°C
Dosing protocol
| Phase | Dose | Frequency | Volume |
|---|---|---|---|
| Weeks 1–2 | 100 mcg | Once daily (SC) | 0.06 mL (6 units) |
| Weeks 3–4 | 150 mcg | Once daily (SC) | 0.09 mL (9 units) |
| Weeks 5–6 | 200 mcg | Once daily (SC) | 0.12 mL (12 units) |
| Weeks 7–12 | 250–300 mcg | Once daily (SC) | 0.15–0.18 mL (15–18 units) |
How it works
CJC-1295 without DAC, also known as modified GRF 1-29, is a 29-amino-acid analog of growth hormone-releasing hormone with four substitutions that improve resistance to enzymatic degradation. Unlike the DAC version, it does not bind albumin, so its half-life is about 30 minutes. This produces a short, discrete GH pulse rather than a sustained elevation. It binds GHRH receptors on pituitary somatotrophs, activating cAMP signaling that increases GH synthesis and secretion. Released GH acts on the liver and other tissues to raise IGF-1, which mediates many anabolic and metabolic effects. Because GHRH-receptor agonists amplify pulses that are still regulated by somatostatin, it is frequently paired with a ghrelin-receptor agonist such as ipamorelin or GHRP-2 to obtain a stronger response. Human data are largely limited to studies of GHRH analogs in general, which show GH and IGF-1 increases, and tesamorelin, a related approved GHRH analog for HIV-associated abdominal fat. Modified GRF 1-29 itself has not completed formal clinical trials and is not approved. Effects on body composition, recovery and aging in healthy people have not been demonstrated in controlled studies.
Units chart for a 5 mg vial
| Water added | Strength | 1 unit = | 100 mcg | 150 mcg | 200 mcg | 250 mcg |
|---|---|---|---|---|---|---|
| 1 mL | 5 mg/mL | 50 mcg | 2 units | 3 units | 4 units | 5 units |
| 2 mL | 2.5 mg/mL | 25 mcg | 4 units | 6 units | 8 units | 10 units |
| 3 mL | 1.67 mg/mL | 16.7 mcg | 6 units | 9 units | 12 units | 15 units |
Units on a U-100 insulin syringe (100 units = 1 mL).
Pages for each vial size and water volume
Reconstitution steps
- Draw 3.0mL bacteriostatic water with a sterile syringe
- Inject slowly down the vial wall; avoid foaming
- Gently swirl/roll until dissolved (do not shake)
- Label and refrigerate at 2–8°C (35.6–46.4°F), protected from light
Storage
Freeze before reconstitution. Refrigerate after. Use within 30 days.
Important notes
- Research use only.
- Best administered on empty stomach.
- Often combined with Ipamorelin or GHRP-2.
Supplies
- CJC-1295 No DAC vial (5mg)
- Bacteriostatic water
- Insulin syringes
- Alcohol swabs